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SUMMARY 
The cerebrospinal fluid (CSF) of normal humans contains both true and pseudo- 
cholinesterases and choline acetyl transferase (choline acetylase) detectable by radio- 
chemical assay. Elevations of total cholinesterase, pseudocholinesterase, and true 
cholinesterase occur in brain tumors, meningitis, Guillain-Barre disease, hydroce- 
phalus, and brain abscess. However, the non-specificity and inconstancy of CSF 
cholinesterase changes in neurologic diseases limit its clinical usefulness. 
Choline acetylase levels in CSF are normally 0.187 * 0.073 nmoles ACh/ml CSF/ 
min. One patient with meningioma had a level of 0.680. Unlike cholinesterase, choline 
acetylase levels in blood are lower than in CSF. Hence, the origin of elevated CSF 
choline acetylase activity is probably in the nervous system. 
Ih’TRODUCTION 
Measurement of serum enzymes provides a useful diagnostic clue in patients 
with hepatitis, myocardial infarction, muscular dystrophy, and other somatic diseases. 
By analogy, one might expect enzymes released into the cerebrospinal fluid (CSF) 
from the brain to help in the diagnosis of neurologic diseases. However, assay of 
spinal fluid enzymes has not gained widespread clinical acceptance. Earlier studies 
of CSF enzymes have been criticized because the origin of these enzymes is not clear. 
We have reexamined CSF cholinesterases, reviewed previous reported changes in CSF 
cholinesterase in diseases of the nervous system, and sought further correlations be- 
tween cholinesterases and neurologic disease. In addition, we applied a similar 
approach to the enzyme choline acetylase (choline acetyltransferase) which, to our 
knowledge, has not previously been measured in human CSF. 
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METHODS 
Chohzesterase 
Acetyl- and butyrylcholinesterase were assayed using the radiochemical tech- 
nique of Siakotos et al.‘. Activity was measured as the rate of hydrolysis of various 
r4C-labelled choline ester substrates. After IO min incubation with CSF at 37’, 
addition of Amberlite CG-IZO cation-exchange resin was used to bind unhydrolyzed 
substrate. Initial substrate concentration was 3 . IO-~ 111 and contained enough 
radioactivity to yield 20 ooo disintegrations per minute. Acetylcholinesterase (“total” 
TABLE I 
CHOLI~ESTERASE ACTIVITY IN NEUROLOGIC DISEASES 
Disease Number Mean CSF Cholinesterasa activity in 
;Lnts 
protein in nmoles substrate/ml CSFlmin 
mg % Mean and standard deviation fov each 
substrate 
































17.j 5 4.1 1.2 + 0.9 II.3 & 2.9 
21.6 i 7.2 1.2 i 0.6 40.1 5 26.2 
19.9 i j.8 2.4 + 2.1 Ij.0 + j.8 
20.7 & 10.6 0.1 * 0.2 21.5 * 16.5 
28.5 i 3.3 0.6 3 0.7 62.5 & 5.0 
22.7 * 3.2 0.9 * 1.3 jJ.0 * 42.1 
22.9 I_t 11.0 2.1 + 1.7 IO.1 * 4.7 
21.7 3.7 6.6 
IO.3 0.1 24.9 
17.4 0.9 19.7 
22.4 0.7 6.9 
20.0 0.6 11.9 
3.5 I.5 10.3 
21.3 0.7 12.0 
32.7 2.2 13.5 
20.7 2.2 11.2 
Fig. 1. Loss of enzyme activity on storage at ~ 25’ C. The activity of both total cholinesterase and 
choline acetylase on storage is shown. The slight loss of enzyme activity during the experiment was 
not significant (see details under Methods). 
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cholinesterase) activity was measured using [I-%] acetyl choline substrate. Metha- 
choline hydrolysis (“true” cholinesterase) was measured using [I-rKacetyl] beta 
methacholine plus 5 . IO@ M tetra-isopropylpyraphosphoramide (iso-OMPA), a 
butyrylcholinesterase inhibitor. Since iso-OMPA also inhibits acetylcholinesterase 
somewhat, our values are lower than previously reported activities (see Table I). 
Rutyrylcholinesterase (“pseudocholinesterase”) activity was determined with [I-%- 
butyrylcholine substrate plus IO-~ M R.W. 28451, a true cholinesterase inhibitor. 
Samples of CSF were assayed in batches. Mean storage time of samples was 
15 days, a maximum storage time was 33 days in one instance. Fig. I shows that a 
slight loss of cholinesterase activity did occur in storage at -25’ C. However, mean 
storage time of the samples in the various diagnostic categories did not significantly 
differ. 
Choline acetylase 
Choline acetylase was assayed by a radiochemical method based on the work of 
McCaman and Hunt2 and Schrier and Shuster3. In this assay, choline acetylase forms 
acetylcholine from excess choline (IO-~ M) and 14C-labelled acetyl-coenzyme A (6.25 
10-4 M, 20 ooo cpm). The labeled acetylcholine formed was separated on prewashed 
8 cm Dowex 1-X8 Cl (200-400 mesh) columns. The purified acetylcholine radioactivity 
was determined on a scintillation counter. 
Since the CSF contains only small amounts of choline acetylase activity, sam- 
ples were concentrated IO times by lyophilization before assay. Aliquots of pooled CSF 
from 25 patients were run with each batch of choline acetylase assays to control the 
uniformity of the procedure. 
Loss of rat brain homogenate choline acetylase activity with storage is also 
shown in Fig. I. Mean storage time of samples was 65 days, ranging from 14 to 99 days. 
Mean storage times of samples in the various diagnostic categories did not significantly 
differ. 
Proteilz 
Cerebrospinal fluid protein was determined by the method of Lowry et a1.4 
Cerebrospinal juid 
Cerebrospinal fluid was obtained from three sources :(a) patients with neurologic 
diseases had lumbar punctures performed by the clinical staff of the Neurology, 
Neurosurgery and Pediatrics Departments. The fluid was kept refrigerated for a 
maximum of 48 h at 4’ before freezer storage at -25’. (1~) CSF was obtained at pneu- 
moencephalography to determine if any relationship existed between the amount of 
fluid withdrawn, the protein concentration, and enzyme activity. With the patient 
sitting, serial samples of fluid were withdrawn as increasing amounts of air were 
injected. CSF not needed for other clinical measurements was saved for enzyme ana- 
lysis. (c) Five samples of 2 ml CSF from normal volunteers was obtained through the 
courtesy of Professor W. W. Tourtelotte of the Neurology Department. Samples of 
20 ml CSF were obtained by lumbar puncture at the rate of I ml/min. The samples 
were spun down and the supernatant frozen at -80” in I ml aliquots. The samples had 
been frozen 8 months at the time of assay. 
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DIAGNOSTIC CATEGORIES 
Patients were assigned to diagnostic categories according to information ob- 
tained from their hospital records. The following criteria were used: 
(I) Normal controls : (a) CSF from 5 normal college student volunteers courtesy 
of \\‘.U:.T. (see above). The students had a normal review of systems, no history of 
metabolic, neurologic, or other disease, and no history of drug abuse. They had normal 
neurologic examinations, CSI; cell counts, VDRL’s, and CSF protein levels. This 
group was used for choline acetylase assays only. (b) In patients who had had exten- 
sive clinical and laboratory workups, but who had no pathologic findings, or at most a 
diagnosis of “neurosis.” 
(2) Hydrocephalus : Bulging fontanelle, head circumference two standard de- 
viations or more above normal for age, signs of increased intracranial pressure, on 
ventriculography no sign of a mass or lesion. 
(3) Multiple sclerosis: Evidence of multiple central nervous system (CNS) 
lesions both spatially and temporally, usually including retrobulbar neuritis. 
(4) Senile dementia: Signs of disorientation and loss of recent memory in a 
person over 50 years old. On pneumoencephalography, cortical atrophy and/or 
ventricular dilatation were present but no evidence of a mass or lesion. 
(5) Leukemia or lymphoma involving CNS. Histologic evidence of leukemia or 
lymphoma. History of seizures beginning after onset of disease, with malignant cells 
in the CSF. 
(6) Meningitis: Fever, stiff neck, CSF leukocytosis plus appropriate bacterial 
cultures of CW. 
(7) Seizure disorder: History typical of psychomotor or grand ma1 epilepsy, and 
EEG evidence of seizure focus. No mass or lesion was demonstrable. 
(8) Guillain-Barre : Largely reversible ascending paralysis associated with a 
previous upper respiratory infection and large CSF protein elevation. 
“umor: Both primary brain and metastatic tumors provided by histologic 
exami%on. 
(IO) Herniated disk: Myelography and operative confirmation. 
The other diagnoses were made by the clinical staff at University Hospital, but 
full diagnostic details will not be given. 
RESULTS 
Surprisingly, cholinesterase activity in the CSF did not vary with CSP total 
protein nor with the amount of CSF withdrawn (up to 30 ml) in a patient with cerebel- 
lar atrophy. Vie obtained similar results in a patient with multiple sclerosis, one with 
senile dementia, and one who developed thalamic pain two years after a stroke. In a 
fifth patient who had psychomotor epilepsy, the graph showed a rough correlation 
between butyrylcholinesterase activity and total protein, but a coefficient of correla- 
tion was not significant. Hence, we express CSF cholinesterase activity per unit volume 
of CSF. 
Table I shows cholinesterase activity in the CSP of patients with neurologic 
disease. The following results differ significantly from normal as measured by the 
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student’s two tailed t-test: low true cholinesterase activity in leukemia-lymphoma; 
elevated protein, total choline&erase, and pseudocholinesterase activity in Guillain- 
Barr& disease; and elevated pseudocholinesterase activity in meningitis. Total protein 
in meningitis, and pseudocholinesterase activity in hydrocephalus, had l-values such 
that P =: 0.06, and these values would probably be significantly elevated in a larger 
series. 
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NL Of CSF REMOVED 
Fig. 2. Change in choline acetylase activity and protein concentration with removal of spinal fluid. 
Choline acetylase activity fluctuated as spinal fluid was withdrawn and appeared to vary with 
protein concentration in CSF. Hence, choline acetylase activity was expressed both per ml CSF 
and per mg CSF protein (see Discussion). 
CsF CHOLINE ACETYLASE ACTIVITY IN NEUROLOGIC DISEASES 
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Fig. 2 shows graphically the relationships among the amount of CSF withdrawn, 
the choline acetylase activity and the total protein concentration in CSF in a patient 
with senile dementia. Choline acetylase activity which is extremely low in CSF seems 
to vary with total protein concentration. In another patient who had multiple sclerosis, 
the choline acetylase activity appeared to vary with the protein, too. The coefficient 
of correlation between protein and choline acetylase activity was not significant using 
data from only two patients, however. Hence, we have expressed choline acetylase 
activity both per ml of CSF and per mg CSF protein. 
Table II shows CSF choline acetylase activity in neurologic diseases. The normal 
level varies from o to about 0.35 nmoles per ml CSF per min or from o to about 0.60 
nmoles per mg CSF protein per min. None of the diagnostic groups differed signifi- 
cantly from normal. However, a patient with a meningioma had levels over 4 S.D. 
above the normal mean whether expressed per ml of CSF or per mg CSF protein. A 
sample from one of the patients with CNS leukemia and one of the samples from the 
patient with Leber’s hereditary optic atrophy were well above the normal range 
expressed per mg CSF protein. 
DISCUSSION 
To make sense of the measurement of cholinesterase in CSF, several questions 
must be answered: Where does the cholinesterase come from ? Does the concentration 
of cholinesterase vary with the source of the sample, i.e., lumbar, cisterna magna or 
ventricular ? Does the protein concentration or the number of cells present affect the 
activity ? In general, neurons and erythrocytes contain most of the true cholinesterase ; 
pseudocholinesterase is found predominantly in glial cells and in serum-*. Studies 
on pathological specimens reveal decreased cholinesterase activity in multiple sclerotic 
plaque9 and increased pseudocholinesterase activity in brain tumor tissue’“. Cholin- 
esterase in CSF might originate from any of these sites. 
Concerning possible sampling variations in CSF cholinesterase activity, our 
data show remarkably constant activity, whether the first or the 33th ml of CSE 
withdrawn is assayed. Surprisingly, our data show that CSF cholinesterase activity 
and total protein vary independently. Colling and Rossiterll reported a significant 
correlation between pseudocholinesterase activity and total CSF protein. Jeffersoni 
and Tower and MacEacllern13 reported correlation between pseudocholinesterase and 
total protein only when total protein levels are greater than 50 mg”/. To explain the 
apparent contradiction, note that cholinesterase has one of the highest substrate 
turnover numbers of any enzyme. Thus, cholinesterase activity could change greatly 
with little increase in total protein. Furthermore, Colling and Rossiter’s report in- 
cluded many cases of meningitis, where the blood-cerebrospinal fluid barrier is known 
to have increased permeability to plasma proteins. Influx of plasma protein, which 
contains high pseudocholinesterase activity, would account for a simultaneous rise 
and a significant correlation between the two. 
The number of cells in the CSF has little effect on cholinesterase activity. 
Leukocytes have insignificant cholinesterase levels 14y15. Birkhauserlc, Collin and Ros- 
siter”, and Tower and MacEacllern13 observed no correlation between cholinesterase 
activity and CSF leukocyte counts. Similarly, Tower and MacEachern13 observed no 
relationship between CSF erythrocyte counts and cholinesterase activity. A theoretical 
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computation based on their data shows that 2000 erythrocytes/mm3 would raise the 
normal rate of acetylcholine hydrolysis by only 10%. 
Changes in cholinesterase activity in neurological diseases reported in this paper 
and by previous investigators are summarized in Table III. The table is organized 
according to the possible origins of CSF cholinesterase discussed earlier. Thus, in 
diseases where the blood-cerebrospinal fluid barrier is abnormally permeable, plasma 
cholinesterase, i.e., pseudocholin~sterase, may leak into the c~rebrospinal fluid. This 
may explain the increased pseudocholinesterase activity described in meningitis, 
Guillain-Barre disease, and hydrocephalus. Similarly, some brain and spinal cord 
tumors contain high levels of cholinesterase, and elevations of CSF total cholinesterase 
have been observed in patients with brain tumor. Destruction of brain parenchyma 
would be expected to release brain cholinesterase into the CSF, and this may be the 
mechanism of elevated cholinesterase levels found in the CSF of some patients with 
brain abscess. Finally, low levels of cholinesterase have been reported in multiple 
sclerotic plaques, and the most extensive investigation of CSF cholinesterase in multi- 
ple sclerosis patients showed low levels of true cholinesterase activityls. The reports 
of Jeffersonlz, Webster and MacKenzie20 and our own data show no difference between 
normal and multiple sclerosis in CSF pseudocholinesterase activity. Our data and that 
of JeffersonI do not confirm the findings of Plum and Fog15 of decreased true cholin- 
esterase activity in multiple sclerosis, but we tested far fewer patients than Plum and 
Fog. 
TABLE III 
CSF CXOLIXESTERASE CHANGES IN NEUROLOGIC DISEASE, 
ARRANGED BY PROBABLE ORIGIN OF CHOLINESTERASE 
A. Plasma-Abnormally permeable blood-CSF barrier 
(I) Meningitis - elevation of pseudocholinesterase~~,~~~~’ and our results. 
(2) Guillain-RarrP - elevation of pseudocholinesterasel* and our results 
(3) Hydrocephalus - elevated pseudocholinesterase -.. our results. 
B. Brain tumor -. elevation of total cholinesterase activity” 
C. Destruction of brain parench~lna - abscess - elevation of total cholinesterase activity I7 
D. Multiple sclerotic plaques - decreased true cholinesterase Is 
I?. Other - myasthenia gravis - elevated true cholinesterasel* 
_. 
Despite a theoretical framework to account for changes in CSF cholinesterase, 
the practical signi~cance of the changes is minimal. Cholinesterase elevations in 
disease states are either non-specific or do not occur in enough of the patients with the 
disease to be of help in diagnosis. In a large number of neurological and psychiatric 
diseases, cholinesterase activity is norma111~‘7~**~2”-25. 
Choline acetylase is present in cerebrospinal fluid, but in very much smaller 
quantity than cholinesterase. The ratio of normal mean enzyme levels in CSF is 
about I part choline acetylase to IOO parts cholinesterase. When levels are expressed 
as enzyme activity per mg protein, the ratios of brain enzyme to CSF enzyme are 
surprisingly similar for cholinesterase and choline acetylase. The average cortical total 
cholinesterase is 152, and the caudate nucleus total cholinesterase 7,602 ~1 CO,/g 
wet brain/10 min, as reported by Okinaka et al. 5. Bull et aLz6 reported choline acetylase 
activity of 190 in gray matter of cortical area 4, and 3790 ,ug ACh/g fresh brain/h in 
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caudate nucleus. Using our data of 46.6 nmoles ACh/mg CSF protein/min for total 
cholinesterase, 0.348 nmoles ACh/mg CSF protein/min for choline acetylase activity in 
normal CSF, and IOO mg protein per gram brain tissue, we obtained the following ratios 
after conversion of units: Choline acetylase/mg protein: CSF/cortex=1.6, CSlT/cau- 
date = 0.08, caudate/cortex = 20. Total cholinesterase/mg protein: CSl;/cortex = 6.7, 
CSF/caudate = 0.14, caudate/cortex = 50. That these ratios are so similar suggests 
that both enzymes normally reach the spinal fluid from the same source, probably 
brain tissue. However, unlike cholinesterase, choline acetylase is not found in high 
concentrations in serum and erythrocytes. Using the same assay method as for CSI;, 
we found that serum choline acetylase activity is about the same or less than that in 
CSF, while erythrocyte activity is about twice as high as CS1; activity. Hence, blood 
is not an important source of elevated CSIT choline acetylase activity. 
The results in Table II demonstrate that choline acetylase is normally present in 
CSF and that it can be elevated in patients with neurologic disease. Its clinical use- 
fulness, if any, awaits the findings of elevated CSl; choline acetylase in a neurologic 
disease not better diagnosed by other methods. Neurologic diseases involving active 
destruction of brain tissue might be expected to show higher than normal CSF choline 
acetylase activity. 
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